By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Reata Pharmaceuticals, Inc. 

1950 Stemmons Freeway, Suite 5001

Dallas  Texas  75207  U.S.A.
Phone: 214-800-8700 Fax: 214-722-0867


SEARCH JOBS


Industry
Pharmaceutical






Company News
Reata Pharmaceuticals, Inc. Announces Second Quarter 2017 Financial and Operating Results 8/15/2017 8:33:02 AM
Reata Pharmaceuticals, Inc. Release: FDA Confirms That Use Of mFARS As Primary Endpoint In Part 2 Of The MOXIe Trial Can Support Approval Of Omaveloxolone In Friedreich’s Ataxia 8/14/2017 8:22:30 AM
Reata Pharmaceuticals, Inc. Announces Closing Of Class A Common Stock Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares 8/1/2017 12:25:53 PM
Reata Pharmaceuticals, Inc. Announces Pricing Of Class A Common Stock Public Offering 7/27/2017 11:20:49 AM
Reata Pharmaceuticals, Inc. Announces Proposed Public Offering Of Class A Common Stock 7/26/2017 10:56:08 AM
Reata Pharmaceuticals, Inc.’s Bardoxolone Methyl Demonstrated Improved Kidney Function In Patients With Alport Syndrome In Ongoing Phase II Portion Of Phase II/III Cardinal Study 7/24/2017 11:03:23 AM
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation For Bardoxolone Methyl For The Treatment Of Alport Syndrome 7/10/2017 10:40:17 AM
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation For Omaveloxolone For The Treatment Of Friedreich’s Ataxia 6/22/2017 11:16:39 AM
Reata Pharmaceuticals, Inc. Announces Positive Data From Part One Of Moxie Trial Of Omaveloxolone For Friedreich’s Ataxia 6/2/2017 8:30:14 AM
Reata Pharmaceuticals, Inc. Announces First Quarter 2017 Financial And Operating Results 5/11/2017 11:15:57 AM
123456
//-->